Board of Directors

Hironori Ando

NapaJen Pharma

Mr. Ando is the CEO and co-founder of NapaJen. He has been active in international business in Japan and the United States for more than 20 years and has played senior roles in the biotech field during much of that period. He co-founded NapaJen in December 2004 with Dr. Kazuo Sakurai upon returning from a 12-year assignment in the U.S. At NapaJen he has spearheaded the vision of growth of the company and funding efforts from grant, private investment and special public-private major awards. He has also built outstanding technical, business and advisory teams and managed intellectual property and legal affairs.

Koichi Ashida, M.Sc.

Innovation Network Corporation of Japan

Mr. Ashida is a Managing Director and Healthcare Team Leader at Innovation Network Corporation of Japan (INCJ). He has extensive experience in pharmaceutical and biotechnology industries as well as more than 15 years of experience in private equity investment. Prior to INCJ, he was co-founder and Managing Partner of Fast Track Initiative, Inc., a Japanese venture capital firm specializing in life science and healthcare. Earlier he held various roles at Amersham Pharmacia Biotech (now GE Healthcare) in Tokyo and in Sweden, and for the Pharmaceutical Business division of Monsanto Japan, Advantage Partners, Inc., a Japanese private equity investment firm and for Bain & Company in Tokyo. Mr. Ashida holds an M. Sc. in the field of Biochemistry from the University of Tokyo.

Kinji Fuchikami, M.Sc.

Mitsui & Co. Global Investments

Mr. Fuchikami is a Venture Partner at Mitsui Global Investments (MGI). He has over 10 years of experience in research, drug discovery and preclinical development. Prior to joining MGI, he worked for 12 years at Research Center Kyoto, at Bayer Yakuhin, Ltd. At Bayer, his primary focus was kinase inhibitors, respiratory diseases, inflammatory diseases and allergy. Mr. Fuchikami holds an M.Sc. in Medical Sciences from Osaka University Medical School.

Maya Fujita, M.Sc.

Innovation Network Corporation of Japan

Ms. Fujita has been with Innovation Network Corporation of Japan (INCJ) since 2013, working on multiple projects in the Life Science and Healthcare area. Prior to joining INCJ, she worked in oncology clinical development at Boehringer-Ingelheim. Ms. Fujita holds an M. Sc. in the field of Medical Science from the University of Tokyo.